Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSPLIMA, Clarice Antunes deGONCALVES, Fabio Augusto RodriguesBESEN, Bruno Adler Maccagnan PinheiroPEREIRA, Antonio Jose RodriguesPERAZZIO, Sandro FelixTRINDADE, Evelinda MarramonFONSECA, Luiz Augusto MarcondesSUMITA, Nairo MassakazuPINTO, Vanusa BarbosaDUARTE, Alberto Jose da SilvaMANIN, Carolina BrocoLICHTENSTEIN, Arnaldo2023-08-162023-08-162023CLINICS, v.78, article ID 100178, 7p, 20231807-5932https://observatorio.fm.usp.br/handle/OPI/54807Objective: COVID-19 is associated with an elevated risk of thromboembolism and excess mortality. Difficulties with best anticoagulation practices and their implementation motivated the current analysis of COVID-19 patients who developed Venous Thromboembolism (VTE). Method: This is a post-hoc analysis of a COVID-19 cohort, described in an economic study already published. The authors analyzed a subset of patients with confirmed VTE. We described the characteristics of the cohort, such as demographics, clinical status, and laboratory results. We tested differences amid two subgroups of patients, those with VTE or not, with the competitive risk Fine and Gray model. Results: Out of 3186 adult patients with COVID-19, 245 (7.7%) were diagnosed with VTE, 174 (5.4%) of them dur-ing admission to the hospital. Four (2.3% of these 174) did not receive prophylactic anticoagulation and 19 (11%) discontinued anticoagulation for at least 3 days, resulting in 170 analyzed. During the first week of hospitaliza-tion, the laboratory most altered results were C-reactive protein and D-dimer. Patients with VTE were more criti-cal, had a higher mortality rate, worse SOFA score, and, on average, 50% longer hospital stay. Conclusion: Proven VTE incidence in this severe COVID-19 cohort was 7.7%, despite 87% of them complying completely with VTE prophylaxis. The clinician must be aware of the diagnosis of VTE in COVID-19, even in patients receiving proper prophylaxis.engopenAccessCOVID-19BiomarkersCohort studiesVenous thromboembolismImmunothrombosisdeep-vein thrombosisvenous thromboembolismenoxaparininfectionriskarticleCopyright ELSEVIER ESPANA10.1016/j.clinsp.2023.100178Medicine, General & Internal1980-5322